KA/EN
Register
Medicines reference
Search
Search
Product

Superium Panacea

Favourites

Lufenuron + Nitenpyram + Moxidectin + Praziquantel · Inter Lek LLC / Collar Company LLC, Interlek

8 forms: tablet. In force in Georgia: 8 of 8 (veterinary register).

Forms and doses8 of 8 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
20/6/0.6/10 mg tablet N1 for cats 0.5-2 kg, Tablet · Cat 0.5–2 kg Cat 0.5–2 kg 1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 · one complete tablet; repeat schedule depends on indication		 one complete tablet; repeat schedule depends on indication Georgia Yes, veterinary
In force until 15 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000953
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Superium Panacea 20/6/0.6/10 mg tablet N1 for cats 0.5-2 kg, Tablet

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
6.3/10
Situational / acceptable
vetman assessment

Superium Panacea

20/6/0.6/10 mg tablet N1 for cats 0.5-2 kg
Assessed clinical scopeCat · Full labelled feline oral scope: fleas and FAD, listed sarcoptiform and demodectic mites, gastrointestinal nematodes and cestodes, mixed infestations and heartworm-larval prevention · By mouth
Care settingVeterinary-selected home administration after parasite-risk assessment, with diagnostic follow-up when treating established infestation
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 000953 · Verified on 21 Oct 2026

A convenient broad oral option with encouraging exact-product feline data, but not a strongly validated substitute for better-documented parasite-specific choices. Use after confirming the actual parasite spectrum and plan follow-up, especially for cestodes.

Regulatory and scientific credibility6.5/10

The exact feline strengths are currently registered in Georgia and have a valid prescription registration plus a detailed regulator-approved SPC in Moldova. The dossier is much less transparent than an EMA/FDA assessment and the broad label is supported mainly by small regional studies.

Clinical efficacy6.0/10

Small exact-product studies support flea and ear-mite activity and suggest benefit in mixed infestations, while established lufenuron/nitenpyram and moxidectin/praziquantel evidence supports component plausibility. The full mite, nematode, cestode and heartworm-prevention label has not been confirmed by robust controlled trials; one 54-cat report found residual Dipylidium segments requiring separate praziquantel.

Safety and tolerability5.5/10

Small studies report good short-term tolerance, but the approved SPC lists rare tremor, seizures, depression, vomiting and gastrointestinal dysfunction. Robust target-animal safety, reproductive and interaction datasets for the four-drug combination are not publicly available; pregnancy and lactation are restricted.

Clinical practicality7.5/10

A single whole weight-banded tablet can consolidate several parasite targets and is given monthly for continuous flea or heartworm prevention. It must not be split, complete swallowing must be observed, and voluntary tablet acceptance in cats is variable; established infestations may need repeat dosing and laboratory follow-up.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with known hypersensitivity, in emaciated animals or animals with infectious disease, or below 6 weeks of age or 0.5 kg body weight.
  • Do not administer concurrently with another antiparasitic. The regulator-approved feline SPC states that interaction data are unavailable; review all current medicines before use.
  • Rare neurological or gastrointestinal reactions can include tremor, seizures, depression, vomiting and digestive dysfunction. Stop and assess promptly if neurological signs, persistent vomiting or marked depression occurs.
  • Avoid during pregnancy and lactation unless a veterinarian determines that expected benefit outweighs risk; exact-combination reproductive safety is not established.
  • This tablet does not treat adult Dirofilaria and is not protection against ixodid pasture ticks. Test and stage heartworm risk as clinically appropriate and choose separate tick control when exposure exists.
  • Use the exact whole tablet for the current body-weight band; do not divide. Give with food or directly by mouth and observe complete swallowing. Reweigh growing or borderline patients before the next dose.
  • The exact-product feline studies are small and cover only part of the label. Recheck established mixed infection; one 54-cat report found persistent Dipylidium segments in isolated cases and used separate praziquantel.
Assessment sources
  1. Superium Panacea
  2. Georgia NFA register 20262026
  3. Lufenuron-nitenpyram flea field study2001
  4. Moxidectin-praziquantel study2016
  5. Moldova ANSA SPC 20242024
  6. Moldova ANSA register2026
  7. Superium cat flea and ear-mite study2024
  8. Superium feline mixed-infestation study2022
  9. Superium feline ear-mite study2023
  10. Superium feline flea study2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lufenuron20 mg/tablet Nitenpyram6 mg/tablet Moxidectin0.6 mg/tablet Praziquantel10 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer (register)
INTER LEK LTD, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1513, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 15 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000953
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 Cat 0.5–2 kg By mouth one complete tablet; repeat schedule depends on indication
Superium Panacea
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Superium Panacea tablets - current official product instruction
Superium official veterinary product instruction
20/6/0.6/10 mg tablet N1 for dogs 0.5-2 kg, Tablet · Dog 0.5–2 kg Dog 0.5–2 kg 1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 · one complete tablet; repeat schedule depends on indication		 one complete tablet; repeat schedule depends on indication Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000999
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Superium Panacea 20/6/0.6/10 mg tablet N1 for dogs 0.5-2 kg, Tablet

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
5.6/10
Weak evidence support
vetman assessment

Superium Panacea

20/6/0.6/10 mg tablet N1 for dogs 0.5-2 kg
Assessed clinical scopeDog · Full labelled canine oral scope: fleas and FAD, lice, listed sarcoptiform and demodectic mites, gastrointestinal nematodes and cestodes, mixed infestations and heartworm-larval prevention · By mouth
Care settingVeterinary-selected home administration after parasite-risk assessment, with diagnostic follow-up when treating established infestation
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000999 · Verified on 21 Oct 2026

Mechanistically plausible and locally registered, but the exact canine combination has too little independent evidence for its very broad label. Prefer better-documented parasite-specific products when available and use this tablet only with explicit diagnostic and follow-up reasoning.

Regulatory and scientific credibility5.5/10

The exact canine strengths are registered in Georgia and have a current manufacturer instruction, but no EMA/FDA-style public assessment or comparable regulator dossier was found. Exact-product independent evidence for dogs was not identified, so ingredient evidence cannot substitute for the combination dossier.

Clinical efficacy5.0/10

The four ingredients have credible activity against their respective targets, including field evidence for lufenuron plus nitenpyram and separate moxidectin/praziquantel data. However, no robust independent trial of this exact canine four-drug tablet was found, so the unusually broad mite, helminth and heartworm-prevention claims remain incompletely validated.

Safety and tolerability5.0/10

The instruction lists rare neurological and gastrointestinal reactions and restricts use in debilitated, infectious, very young or very small animals and with other antiparasitics. Public target-animal safety and interaction data for the exact four-drug canine combination are sparse, and moxidectin warrants particular caution in ABCB1-sensitive dogs.

Clinical practicality8.0/10

One whole monthly weight-banded tablet can consolidate several parasite targets and avoids topical residue. Five canine weight bands support dose selection, but the tablet must not be split, complete swallowing must be confirmed and treatment schedules differ by parasite, with reassessment or repeat dosing for mites and severe helminth infection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with known hypersensitivity, in emaciated animals or animals with infectious disease, or below 6 weeks of age or 0.5 kg body weight.
  • Do not administer concurrently with another antiparasitic. The regulator-approved feline SPC states that interaction data are unavailable; review all current medicines before use.
  • Rare neurological or gastrointestinal reactions can include tremor, seizures, depression, vomiting and digestive dysfunction. Stop and assess promptly if neurological signs, persistent vomiting or marked depression occurs.
  • Avoid during pregnancy and lactation unless a veterinarian determines that expected benefit outweighs risk; exact-combination reproductive safety is not established.
  • This tablet does not treat adult Dirofilaria and is not protection against ixodid pasture ticks. Test and stage heartworm risk as clinically appropriate and choose separate tick control when exposure exists.
  • Use the exact whole tablet for the current body-weight band; do not divide. Give with food or directly by mouth and observe complete swallowing. Reweigh growing or borderline patients before the next dose.
  • In Collies and other ABCB1-sensitive dogs, use moxidectin-containing treatment only at the exact labelled dose under veterinary supervision; avoid interacting P-glycoprotein substrates unless the individual risk is resolved.
Assessment sources
  1. Superium Panacea
  2. Georgia NFA register 20262026
  3. Lufenuron-nitenpyram flea field study2001
  4. Moxidectin-praziquantel study2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lufenuron20 mg/tablet Nitenpyram6 mg/tablet Moxidectin0.6 mg/tablet Praziquantel10 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer (register)
INTER LEK LTD, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1578, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000999
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 Dog 0.5–2 kg By mouth one complete tablet; repeat schedule depends on indication
Superium Panacea
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Superium Panacea tablets - current official product instruction
Superium official veterinary product instruction
40/12/1.2/20 mg tablet N1 for cats 2-8 kg, Tablet · Cat 2–8 kg Cat 2–8 kg 1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 · one complete tablet; repeat schedule depends on indication		 one complete tablet; repeat schedule depends on indication Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 001001
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Superium Panacea 40/12/1.2/20 mg tablet N1 for cats 2-8 kg, Tablet

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
6.3/10
Situational / acceptable
vetman assessment

Superium Panacea

40/12/1.2/20 mg tablet N1 for cats 2-8 kg
Assessed clinical scopeCat · Full labelled feline oral scope: fleas and FAD, listed sarcoptiform and demodectic mites, gastrointestinal nematodes and cestodes, mixed infestations and heartworm-larval prevention · By mouth
Care settingVeterinary-selected home administration after parasite-risk assessment, with diagnostic follow-up when treating established infestation
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 001001 · Verified on 21 Oct 2026

A convenient broad oral option with encouraging exact-product feline data, but not a strongly validated substitute for better-documented parasite-specific choices. Use after confirming the actual parasite spectrum and plan follow-up, especially for cestodes.

Regulatory and scientific credibility6.5/10

The exact feline strengths are currently registered in Georgia and have a valid prescription registration plus a detailed regulator-approved SPC in Moldova. The dossier is much less transparent than an EMA/FDA assessment and the broad label is supported mainly by small regional studies.

Clinical efficacy6.0/10

Small exact-product studies support flea and ear-mite activity and suggest benefit in mixed infestations, while established lufenuron/nitenpyram and moxidectin/praziquantel evidence supports component plausibility. The full mite, nematode, cestode and heartworm-prevention label has not been confirmed by robust controlled trials; one 54-cat report found residual Dipylidium segments requiring separate praziquantel.

Safety and tolerability5.5/10

Small studies report good short-term tolerance, but the approved SPC lists rare tremor, seizures, depression, vomiting and gastrointestinal dysfunction. Robust target-animal safety, reproductive and interaction datasets for the four-drug combination are not publicly available; pregnancy and lactation are restricted.

Clinical practicality7.5/10

A single whole weight-banded tablet can consolidate several parasite targets and is given monthly for continuous flea or heartworm prevention. It must not be split, complete swallowing must be observed, and voluntary tablet acceptance in cats is variable; established infestations may need repeat dosing and laboratory follow-up.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with known hypersensitivity, in emaciated animals or animals with infectious disease, or below 6 weeks of age or 0.5 kg body weight.
  • Do not administer concurrently with another antiparasitic. The regulator-approved feline SPC states that interaction data are unavailable; review all current medicines before use.
  • Rare neurological or gastrointestinal reactions can include tremor, seizures, depression, vomiting and digestive dysfunction. Stop and assess promptly if neurological signs, persistent vomiting or marked depression occurs.
  • Avoid during pregnancy and lactation unless a veterinarian determines that expected benefit outweighs risk; exact-combination reproductive safety is not established.
  • This tablet does not treat adult Dirofilaria and is not protection against ixodid pasture ticks. Test and stage heartworm risk as clinically appropriate and choose separate tick control when exposure exists.
  • Use the exact whole tablet for the current body-weight band; do not divide. Give with food or directly by mouth and observe complete swallowing. Reweigh growing or borderline patients before the next dose.
  • The exact-product feline studies are small and cover only part of the label. Recheck established mixed infection; one 54-cat report found persistent Dipylidium segments in isolated cases and used separate praziquantel.
Assessment sources
  1. Superium Panacea
  2. Georgia NFA register 20262026
  3. Lufenuron-nitenpyram flea field study2001
  4. Moxidectin-praziquantel study2016
  5. Moldova ANSA SPC 20242024
  6. Moldova ANSA register2026
  7. Superium cat flea and ear-mite study2024
  8. Superium feline mixed-infestation study2022
  9. Superium feline ear-mite study2023
  10. Superium feline flea study2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lufenuron40 mg/tablet Nitenpyram12 mg/tablet Moxidectin1.2 mg/tablet Praziquantel20 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer (register)
INTER LEK LTD, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1580, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 001001
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 Cat 2–8 kg By mouth one complete tablet; repeat schedule depends on indication
Superium Panacea
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Superium Panacea tablets - current official product instruction
Superium official veterinary product instruction
40/12/1.2/20 mg tablet N1 for dogs 2-8 kg, Tablet · Dog 2–8 kg Dog 2–8 kg 1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 · one complete tablet; repeat schedule depends on indication		 one complete tablet; repeat schedule depends on indication Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000946
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Superium Panacea 40/12/1.2/20 mg tablet N1 for dogs 2-8 kg, Tablet

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
5.6/10
Weak evidence support
vetman assessment

Superium Panacea

40/12/1.2/20 mg tablet N1 for dogs 2-8 kg
Assessed clinical scopeDog · Full labelled canine oral scope: fleas and FAD, lice, listed sarcoptiform and demodectic mites, gastrointestinal nematodes and cestodes, mixed infestations and heartworm-larval prevention · By mouth
Care settingVeterinary-selected home administration after parasite-risk assessment, with diagnostic follow-up when treating established infestation
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000946 · Verified on 21 Oct 2026

Mechanistically plausible and locally registered, but the exact canine combination has too little independent evidence for its very broad label. Prefer better-documented parasite-specific products when available and use this tablet only with explicit diagnostic and follow-up reasoning.

Regulatory and scientific credibility5.5/10

The exact canine strengths are registered in Georgia and have a current manufacturer instruction, but no EMA/FDA-style public assessment or comparable regulator dossier was found. Exact-product independent evidence for dogs was not identified, so ingredient evidence cannot substitute for the combination dossier.

Clinical efficacy5.0/10

The four ingredients have credible activity against their respective targets, including field evidence for lufenuron plus nitenpyram and separate moxidectin/praziquantel data. However, no robust independent trial of this exact canine four-drug tablet was found, so the unusually broad mite, helminth and heartworm-prevention claims remain incompletely validated.

Safety and tolerability5.0/10

The instruction lists rare neurological and gastrointestinal reactions and restricts use in debilitated, infectious, very young or very small animals and with other antiparasitics. Public target-animal safety and interaction data for the exact four-drug canine combination are sparse, and moxidectin warrants particular caution in ABCB1-sensitive dogs.

Clinical practicality8.0/10

One whole monthly weight-banded tablet can consolidate several parasite targets and avoids topical residue. Five canine weight bands support dose selection, but the tablet must not be split, complete swallowing must be confirmed and treatment schedules differ by parasite, with reassessment or repeat dosing for mites and severe helminth infection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with known hypersensitivity, in emaciated animals or animals with infectious disease, or below 6 weeks of age or 0.5 kg body weight.
  • Do not administer concurrently with another antiparasitic. The regulator-approved feline SPC states that interaction data are unavailable; review all current medicines before use.
  • Rare neurological or gastrointestinal reactions can include tremor, seizures, depression, vomiting and digestive dysfunction. Stop and assess promptly if neurological signs, persistent vomiting or marked depression occurs.
  • Avoid during pregnancy and lactation unless a veterinarian determines that expected benefit outweighs risk; exact-combination reproductive safety is not established.
  • This tablet does not treat adult Dirofilaria and is not protection against ixodid pasture ticks. Test and stage heartworm risk as clinically appropriate and choose separate tick control when exposure exists.
  • Use the exact whole tablet for the current body-weight band; do not divide. Give with food or directly by mouth and observe complete swallowing. Reweigh growing or borderline patients before the next dose.
  • In Collies and other ABCB1-sensitive dogs, use moxidectin-containing treatment only at the exact labelled dose under veterinary supervision; avoid interacting P-glycoprotein substrates unless the individual risk is resolved.
Assessment sources
  1. Superium Panacea
  2. Georgia NFA register 20262026
  3. Lufenuron-nitenpyram flea field study2001
  4. Moxidectin-praziquantel study2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lufenuron40 mg/tablet Nitenpyram12 mg/tablet Moxidectin1.2 mg/tablet Praziquantel20 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer (register)
INTER LEK LTD, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1506, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000946
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 Dog 2–8 kg By mouth one complete tablet; repeat schedule depends on indication
Superium Panacea
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Superium Panacea tablets - current official product instruction
Superium official veterinary product instruction
80/24/2.4/40 mg tablet, Tablet · Dog 8–16 kg Dog 8–16 kg 1 tablet
Do not divide. Fleas monthly; ear/notoedric mange once and reassess at one month; sarcoptic mange monthly twice; demodicosis monthly until two negative scrapings; helminths once, repeat after 10-14 days if severe, prevention quarterly; heartworm prevention monthly across vector season.
 · one whole tablet; repeat by indication		 one whole tablet; repeat by indication Georgia Yes, veterinary
In force until 15 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000948
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Superium Panacea 80/24/2.4/40 mg tablet, Tablet

N1 for dogs 8-16 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
5.6/10
Weak evidence support
vetman assessment

Superium Panacea

80/24/2.4/40 mg tablet, N1 for dogs 8-16 kg
Assessed clinical scopeDog · Full labelled canine oral scope: fleas and FAD, lice, listed sarcoptiform and demodectic mites, gastrointestinal nematodes and cestodes, mixed infestations and heartworm-larval prevention · By mouth
Care settingVeterinary-selected home administration after parasite-risk assessment, with diagnostic follow-up when treating established infestation
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000948 · Verified on 21 Oct 2026

Mechanistically plausible and locally registered, but the exact canine combination has too little independent evidence for its very broad label. Prefer better-documented parasite-specific products when available and use this tablet only with explicit diagnostic and follow-up reasoning.

Regulatory and scientific credibility5.5/10

The exact canine strengths are registered in Georgia and have a current manufacturer instruction, but no EMA/FDA-style public assessment or comparable regulator dossier was found. Exact-product independent evidence for dogs was not identified, so ingredient evidence cannot substitute for the combination dossier.

Clinical efficacy5.0/10

The four ingredients have credible activity against their respective targets, including field evidence for lufenuron plus nitenpyram and separate moxidectin/praziquantel data. However, no robust independent trial of this exact canine four-drug tablet was found, so the unusually broad mite, helminth and heartworm-prevention claims remain incompletely validated.

Safety and tolerability5.0/10

The instruction lists rare neurological and gastrointestinal reactions and restricts use in debilitated, infectious, very young or very small animals and with other antiparasitics. Public target-animal safety and interaction data for the exact four-drug canine combination are sparse, and moxidectin warrants particular caution in ABCB1-sensitive dogs.

Clinical practicality8.0/10

One whole monthly weight-banded tablet can consolidate several parasite targets and avoids topical residue. Five canine weight bands support dose selection, but the tablet must not be split, complete swallowing must be confirmed and treatment schedules differ by parasite, with reassessment or repeat dosing for mites and severe helminth infection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with known hypersensitivity, in emaciated animals or animals with infectious disease, or below 6 weeks of age or 0.5 kg body weight.
  • Do not administer concurrently with another antiparasitic. The regulator-approved feline SPC states that interaction data are unavailable; review all current medicines before use.
  • Rare neurological or gastrointestinal reactions can include tremor, seizures, depression, vomiting and digestive dysfunction. Stop and assess promptly if neurological signs, persistent vomiting or marked depression occurs.
  • Avoid during pregnancy and lactation unless a veterinarian determines that expected benefit outweighs risk; exact-combination reproductive safety is not established.
  • This tablet does not treat adult Dirofilaria and is not protection against ixodid pasture ticks. Test and stage heartworm risk as clinically appropriate and choose separate tick control when exposure exists.
  • Use the exact whole tablet for the current body-weight band; do not divide. Give with food or directly by mouth and observe complete swallowing. Reweigh growing or borderline patients before the next dose.
  • In Collies and other ABCB1-sensitive dogs, use moxidectin-containing treatment only at the exact labelled dose under veterinary supervision; avoid interacting P-glycoprotein substrates unless the individual risk is resolved.
Assessment sources
  1. Superium Panacea
  2. Georgia NFA register 20262026
  3. Lufenuron-nitenpyram flea field study2001
  4. Moxidectin-praziquantel study2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lufenuron80 mg/tablet Nitenpyram24 mg/tablet Moxidectin2.4 mg/tablet Praziquantel40 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Interlek
Manufacturer (register)
INTER LEK LTD, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1508, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 15 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000948
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 tablet
Do not divide. Fleas monthly; ear/notoedric mange once and reassess at one month; sarcoptic mange monthly twice; demodicosis monthly until two negative scrapings; helminths once, repeat after 10-14 days if severe, prevention quarterly; heartworm prevention monthly across vector season.
 Dog 8–16 kg By mouth one whole tablet; repeat by indication
Superium Panacea
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Superium Panacea tablets for dogs 8-16 kg - official instruction
Official manufacturer instruction, 2026
80/24/2.4/40 mg tablet N1 for cats 8-16 kg, Tablet · Cat 8–16 kg Cat 8–16 kg 1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 · one complete tablet; repeat schedule depends on indication		 one complete tablet; repeat schedule depends on indication Georgia Yes, veterinary
In force until 15 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000948
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Superium Panacea 80/24/2.4/40 mg tablet N1 for cats 8-16 kg, Tablet

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
6.3/10
Situational / acceptable
vetman assessment

Superium Panacea

80/24/2.4/40 mg tablet N1 for cats 8-16 kg
Assessed clinical scopeCat · Full labelled feline oral scope: fleas and FAD, listed sarcoptiform and demodectic mites, gastrointestinal nematodes and cestodes, mixed infestations and heartworm-larval prevention · By mouth
Care settingVeterinary-selected home administration after parasite-risk assessment, with diagnostic follow-up when treating established infestation
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 000948 · Verified on 21 Oct 2026

A convenient broad oral option with encouraging exact-product feline data, but not a strongly validated substitute for better-documented parasite-specific choices. Use after confirming the actual parasite spectrum and plan follow-up, especially for cestodes.

Regulatory and scientific credibility6.5/10

The exact feline strengths are currently registered in Georgia and have a valid prescription registration plus a detailed regulator-approved SPC in Moldova. The dossier is much less transparent than an EMA/FDA assessment and the broad label is supported mainly by small regional studies.

Clinical efficacy6.0/10

Small exact-product studies support flea and ear-mite activity and suggest benefit in mixed infestations, while established lufenuron/nitenpyram and moxidectin/praziquantel evidence supports component plausibility. The full mite, nematode, cestode and heartworm-prevention label has not been confirmed by robust controlled trials; one 54-cat report found residual Dipylidium segments requiring separate praziquantel.

Safety and tolerability5.5/10

Small studies report good short-term tolerance, but the approved SPC lists rare tremor, seizures, depression, vomiting and gastrointestinal dysfunction. Robust target-animal safety, reproductive and interaction datasets for the four-drug combination are not publicly available; pregnancy and lactation are restricted.

Clinical practicality7.5/10

A single whole weight-banded tablet can consolidate several parasite targets and is given monthly for continuous flea or heartworm prevention. It must not be split, complete swallowing must be observed, and voluntary tablet acceptance in cats is variable; established infestations may need repeat dosing and laboratory follow-up.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with known hypersensitivity, in emaciated animals or animals with infectious disease, or below 6 weeks of age or 0.5 kg body weight.
  • Do not administer concurrently with another antiparasitic. The regulator-approved feline SPC states that interaction data are unavailable; review all current medicines before use.
  • Rare neurological or gastrointestinal reactions can include tremor, seizures, depression, vomiting and digestive dysfunction. Stop and assess promptly if neurological signs, persistent vomiting or marked depression occurs.
  • Avoid during pregnancy and lactation unless a veterinarian determines that expected benefit outweighs risk; exact-combination reproductive safety is not established.
  • This tablet does not treat adult Dirofilaria and is not protection against ixodid pasture ticks. Test and stage heartworm risk as clinically appropriate and choose separate tick control when exposure exists.
  • Use the exact whole tablet for the current body-weight band; do not divide. Give with food or directly by mouth and observe complete swallowing. Reweigh growing or borderline patients before the next dose.
  • The exact-product feline studies are small and cover only part of the label. Recheck established mixed infection; one 54-cat report found persistent Dipylidium segments in isolated cases and used separate praziquantel.
Assessment sources
  1. Superium Panacea
  2. Georgia NFA register 20262026
  3. Lufenuron-nitenpyram flea field study2001
  4. Moxidectin-praziquantel study2016
  5. Moldova ANSA SPC 20242024
  6. Moldova ANSA register2026
  7. Superium cat flea and ear-mite study2024
  8. Superium feline mixed-infestation study2022
  9. Superium feline ear-mite study2023
  10. Superium feline flea study2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lufenuron80 mg/tablet Nitenpyram24 mg/tablet Moxidectin2.4 mg/tablet Praziquantel40 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer (register)
INTER LEK LTD, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1508, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 15 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000948
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 Cat 8–16 kg By mouth one complete tablet; repeat schedule depends on indication
Superium Panacea
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Superium Panacea tablets - current official product instruction
Superium official veterinary product instruction
160/48/4.8/80 mg tablet N1 for dogs 16-30 kg, Tablet · Dog 16–30 kg Dog 16–30 kg 1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 · one complete tablet; repeat schedule depends on indication		 one complete tablet; repeat schedule depends on indication Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 001000
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Superium Panacea 160/48/4.8/80 mg tablet N1 for dogs 16-30 kg, Tablet

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
5.6/10
Weak evidence support
vetman assessment

Superium Panacea

160/48/4.8/80 mg tablet N1 for dogs 16-30 kg
Assessed clinical scopeDog · Full labelled canine oral scope: fleas and FAD, lice, listed sarcoptiform and demodectic mites, gastrointestinal nematodes and cestodes, mixed infestations and heartworm-larval prevention · By mouth
Care settingVeterinary-selected home administration after parasite-risk assessment, with diagnostic follow-up when treating established infestation
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 001000 · Verified on 21 Oct 2026

Mechanistically plausible and locally registered, but the exact canine combination has too little independent evidence for its very broad label. Prefer better-documented parasite-specific products when available and use this tablet only with explicit diagnostic and follow-up reasoning.

Regulatory and scientific credibility5.5/10

The exact canine strengths are registered in Georgia and have a current manufacturer instruction, but no EMA/FDA-style public assessment or comparable regulator dossier was found. Exact-product independent evidence for dogs was not identified, so ingredient evidence cannot substitute for the combination dossier.

Clinical efficacy5.0/10

The four ingredients have credible activity against their respective targets, including field evidence for lufenuron plus nitenpyram and separate moxidectin/praziquantel data. However, no robust independent trial of this exact canine four-drug tablet was found, so the unusually broad mite, helminth and heartworm-prevention claims remain incompletely validated.

Safety and tolerability5.0/10

The instruction lists rare neurological and gastrointestinal reactions and restricts use in debilitated, infectious, very young or very small animals and with other antiparasitics. Public target-animal safety and interaction data for the exact four-drug canine combination are sparse, and moxidectin warrants particular caution in ABCB1-sensitive dogs.

Clinical practicality8.0/10

One whole monthly weight-banded tablet can consolidate several parasite targets and avoids topical residue. Five canine weight bands support dose selection, but the tablet must not be split, complete swallowing must be confirmed and treatment schedules differ by parasite, with reassessment or repeat dosing for mites and severe helminth infection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with known hypersensitivity, in emaciated animals or animals with infectious disease, or below 6 weeks of age or 0.5 kg body weight.
  • Do not administer concurrently with another antiparasitic. The regulator-approved feline SPC states that interaction data are unavailable; review all current medicines before use.
  • Rare neurological or gastrointestinal reactions can include tremor, seizures, depression, vomiting and digestive dysfunction. Stop and assess promptly if neurological signs, persistent vomiting or marked depression occurs.
  • Avoid during pregnancy and lactation unless a veterinarian determines that expected benefit outweighs risk; exact-combination reproductive safety is not established.
  • This tablet does not treat adult Dirofilaria and is not protection against ixodid pasture ticks. Test and stage heartworm risk as clinically appropriate and choose separate tick control when exposure exists.
  • Use the exact whole tablet for the current body-weight band; do not divide. Give with food or directly by mouth and observe complete swallowing. Reweigh growing or borderline patients before the next dose.
  • In Collies and other ABCB1-sensitive dogs, use moxidectin-containing treatment only at the exact labelled dose under veterinary supervision; avoid interacting P-glycoprotein substrates unless the individual risk is resolved.
Assessment sources
  1. Superium Panacea
  2. Georgia NFA register 20262026
  3. Lufenuron-nitenpyram flea field study2001
  4. Moxidectin-praziquantel study2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lufenuron160 mg/tablet Nitenpyram48 mg/tablet Moxidectin4.8 mg/tablet Praziquantel80 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer (register)
INTER LEK LTD, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1579, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 001000
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 Dog 16–30 kg By mouth one complete tablet; repeat schedule depends on indication
Superium Panacea
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Superium Panacea tablets - current official product instruction
Superium official veterinary product instruction
320/96/9.6/160 mg tablet N1 for dogs 30-60 kg, Tablet · Dog 30–60 kg Dog 30–60 kg 1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 · one complete tablet; repeat schedule depends on indication		 one complete tablet; repeat schedule depends on indication Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000947
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Superium Panacea 320/96/9.6/160 mg tablet N1 for dogs 30-60 kg, Tablet

vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
5.6/10
Weak evidence support
vetman assessment

Superium Panacea

320/96/9.6/160 mg tablet N1 for dogs 30-60 kg
Assessed clinical scopeDog · Full labelled canine oral scope: fleas and FAD, lice, listed sarcoptiform and demodectic mites, gastrointestinal nematodes and cestodes, mixed infestations and heartworm-larval prevention · By mouth
Care settingVeterinary-selected home administration after parasite-risk assessment, with diagnostic follow-up when treating established infestation
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000947 · Verified on 21 Oct 2026

Mechanistically plausible and locally registered, but the exact canine combination has too little independent evidence for its very broad label. Prefer better-documented parasite-specific products when available and use this tablet only with explicit diagnostic and follow-up reasoning.

Regulatory and scientific credibility5.5/10

The exact canine strengths are registered in Georgia and have a current manufacturer instruction, but no EMA/FDA-style public assessment or comparable regulator dossier was found. Exact-product independent evidence for dogs was not identified, so ingredient evidence cannot substitute for the combination dossier.

Clinical efficacy5.0/10

The four ingredients have credible activity against their respective targets, including field evidence for lufenuron plus nitenpyram and separate moxidectin/praziquantel data. However, no robust independent trial of this exact canine four-drug tablet was found, so the unusually broad mite, helminth and heartworm-prevention claims remain incompletely validated.

Safety and tolerability5.0/10

The instruction lists rare neurological and gastrointestinal reactions and restricts use in debilitated, infectious, very young or very small animals and with other antiparasitics. Public target-animal safety and interaction data for the exact four-drug canine combination are sparse, and moxidectin warrants particular caution in ABCB1-sensitive dogs.

Clinical practicality8.0/10

One whole monthly weight-banded tablet can consolidate several parasite targets and avoids topical residue. Five canine weight bands support dose selection, but the tablet must not be split, complete swallowing must be confirmed and treatment schedules differ by parasite, with reassessment or repeat dosing for mites and severe helminth infection.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with known hypersensitivity, in emaciated animals or animals with infectious disease, or below 6 weeks of age or 0.5 kg body weight.
  • Do not administer concurrently with another antiparasitic. The regulator-approved feline SPC states that interaction data are unavailable; review all current medicines before use.
  • Rare neurological or gastrointestinal reactions can include tremor, seizures, depression, vomiting and digestive dysfunction. Stop and assess promptly if neurological signs, persistent vomiting or marked depression occurs.
  • Avoid during pregnancy and lactation unless a veterinarian determines that expected benefit outweighs risk; exact-combination reproductive safety is not established.
  • This tablet does not treat adult Dirofilaria and is not protection against ixodid pasture ticks. Test and stage heartworm risk as clinically appropriate and choose separate tick control when exposure exists.
  • Use the exact whole tablet for the current body-weight band; do not divide. Give with food or directly by mouth and observe complete swallowing. Reweigh growing or borderline patients before the next dose.
  • In Collies and other ABCB1-sensitive dogs, use moxidectin-containing treatment only at the exact labelled dose under veterinary supervision; avoid interacting P-glycoprotein substrates unless the individual risk is resolved.
Assessment sources
  1. Superium Panacea
  2. Georgia NFA register 20262026
  3. Lufenuron-nitenpyram flea field study2001
  4. Moxidectin-praziquantel study2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lufenuron320 mg/tablet Nitenpyram96 mg/tablet Moxidectin9.6 mg/tablet Praziquantel160 mg/tablet
Formulation Type
Tablet
Administration route
By mouth
Manufacturer (register)
INTER LEK LTD, Ukraine
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1507, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 12 Sep 2030
Veterinary (National Food Agency)
In the register: სუპერიუმ პანაცეა
№ 000947
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give with food or directly into the mouth and ensure the whole tablet is swallowed; do not divide. Flea control is generally monthly; mite and mange schedules require clinical reassessment; helminth treatment may repeat after 10-14 days in severe infestation; heartworm prevention is monthly through the risk season. Do not use below 6 weeks or 0.5 kg, in emaciated or infectious animals, during pregnancy or lactation without veterinary benefit-risk assessment, or with another antiparasitic. Not effective against adult Dirofilaria.
 Dog 30–60 kg By mouth one complete tablet; repeat schedule depends on indication
Superium Panacea
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Superium Panacea tablets - current official product instruction
Superium official veterinary product instruction
Active substance doses, with sources
Active substance Moxidectin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2.5–6.25 mg/kg Dog Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advocate 400 mg + 100 mg spot-on solution for extra-large dogs (> 25-40 kg) - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
1–2 mg/kg Cat Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advocate 40 mg + 4 mg spot-on solution for small cats (<= 4 kg) and ferrets - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Active substance Praziquantel
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
5 mg/kg Dog, Cat Maintenance By mouth once
VMD SPC 2022
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Krka Multiwormer 50/144/150 mg tablets for dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2022
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Krka Wormer 230 mg/20 mg film-coated tablets for cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024

Lufenuron: No dose supported by a publicly verifiable source yet

Nitenpyram: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical Moxidectin
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical Moxidectin (Dog)
    Do not use in puppies under 7 weeks of age. The safe use... has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs. body weight.
    Sources: VMD SPC · VMD · FDA
  • Critical Moxidectin (Cat)
    Do not use in kittens under 9 weeks of age. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin
    The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species.... The use is not recommended during pregnancy and lactation. Fertility: Do not use in breeding animals. The safety... has not been established in breeding, pregnant, or lactating
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin
    The use is not recommended during pregnancy and lactation.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Dog)
    special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds... in particular, oral uptake by Collie or Old English Sheep dogs and related breeds or crossbreeds should be prevented. Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Dog)
    Do not use in dogs classified as Class 4 for heartworm disease has not been evaluated in heartworm-positive dogs with Class 4 heartworm disease
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Cat)
    use of the veterinary medicinal product on cats or ferrets which have adult heartworms may cause serious adverse effects, including death No adverse reactions were associated with the topical application... to experimentally heartworm-infected cats.
    Sources: VMD SPC · VMD · FDA
  • Warning Moxidectin (Cat)
    Do not use on sick, debilitated, or underweight cats Several otherwise healthy, thin geriatric cats experienced prolonged lethargy and sleepiness after using this drug.
    Sources: VMD SPC · VMD · FDA
  • Caution Moxidectin (Dog)
    Use with caution in sick, debilitated, or underweight animals.
    Sources: VMD SPC · VMD · FDA
  • Critical Praziquantel
    Do not use in cases of known hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Known Breed Sensitivities Moxidectin
    Collie, Collie (unspecified), Collie - Scottish Rough, Collie - Scottish Smooth, Sheepdog - Old English
    special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds... oral uptake... should be prevented.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (80 more) Hide additional products

Same therapeutic group 80

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗